In the mean time, though, the German edition of The Financial Times (quoted by Bloomberg) is indicating that the final, sealed divestiture bids, on perhaps $1.2 billion of the Sanofi-Merck Merial assets, being required by antitrust regulations (and regulators) in the US, Japan, Australia and Europe, are due by month’s end:
. . . .Final bids for animal health assets being sold by Sanofi-Aventis SA and Merck & Co. are due by the end of January, Financial Times Deutschland reported, citing people close to the transaction who were not named.
I’d almost certainly add Abbott and Fort Dodge/Pfizer to that list. Of course, I cannot resist re-running the companion animal graphic of a few months back — which also reminds us that much of this is a legacy Schering-Plough/legacy Organon business.
Be excellent to one another.